Premixed insulin aspart 30 (BIAsp 30) versus premixed human insulin 30 (BHI 30) in gestational diabetes mellitus: a randomized open-label controlled study
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
A randomized, open-label, parallel study was conducted to assess the efficacy and safety of premixed insulin aspart 30 (biphasic insulin aspart [BIAsp] 30) in managing gestational diabetes mellitus (GDM). A total of 323 women with GDM registered at a single center in India were randomly assigned to receive 6 U of either BIAsp 30 (Group A) or premixed human insulin (biphasic human insulin [BHI] 30; Group B) in a 1:1 ratio. Subjects performed home glucose monitoring and visited their care provider twice a month. The primary outcome was the degree of neonatal macrosomia (neonatal birth weight >90th percentile). Groups A and B were demographically comparable at study entry. Before labor onset, Groups A and B achieved similar degrees of fasting plasma glucose and postprandial plasma glucose control (92.97 ± 14.44 vs. 95.43 ± 18.96 and 127.59 ± 28.99 vs. 126.98 ± 29.89, respectively; both p = NS). Neonatal macrosomia frequency was 6.3% in Group A and 6.9% in Group B; however, this difference was not statistically significant. By last visit, the required insulin dose was significantly lower for Group A than Group B (19.83 ± 15.75 IU vs. 26.34 ± 23.15 IU, respectively; p = 0.006). BIAsp 30 was noninferior to BHI 30, producing comparable fetal outcomes when administered during pregnancy. Based on final doses, BIAsp 30 may offer greater treat-to-target potential for pregnant women.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Defining and Reporting Hypoglycemia in Diabetes
American Diabetes Association Workgroup on Hypoglycemia (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1245 · Cited by 1,146
Maternal postprandial glucose levels and infant birth weight: the diabetes in early pregnancy study
Jovanovic-Peterson, L., Peterson, C. M., Reed, G. F., Metzger, B. E., Mills, J. L., Knopp, R. H., & Aarons, J. H. (1991) · American Journal of Obstetrics and Gynecology · doi:10.1016/0002-9378(91)90637-7 · Cited by 411
HbA1c levels are significantly lower in early and late pregnancy
Nielsen, L. R., Ekbom, P., Damm, P., Glümer, C., Frandsen, M. M., Jensen, D. M., & Mathiesen, E. R. (2004) · Diabetes Care · doi:10.2337/diacare.27.5.1200 · Cited by 331
Cited by
EADSG Guidelines: Insulin Therapy in Diabetes
Silver, B., Ramaiya, K., Andrew, S. B., Fredrick, O., Bajaj, S., Kalra, S., Charlotte, B. M., Claudine, K., & Makhoba, A. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0384-6 · Cited by 179
“However, premix insulin analogues offer flexible dosing and a high safety profile compared with premix human insulin [110].”
BackgroundInsulin for the treatment of women with gestational diabetes
Brown, J., Grzeskowiak, L., Williamson, K., Downie, M. R., & Crowther, C. A. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012037.pub2 · Cited by 158
Safety of insulin analogs during pregnancy: a meta-analysis
Lv, S., Wang, J., & Xu, Y. (2015) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-015-3692-3 · Cited by 88
Caissutti, C., Saccone, G., Khalifeh, A., Mackeen, A. D., Lott, M., & Berghella, V. (2019) · The Journal of Maternal-Fetal & Neonatal Medicine · doi:10.1080/14767058.2018.1449203 · Cited by 13
“Regarding the glucose values used for starting pharmacologic therapy after diet and exercise, there were seven different criteria that the included studies applied: Thirteen trials (87%) used 1 or 2 values higher than the target values [1,2,4–13,15]; of these, 7/13 (54%) used 1 value higher than target values [2,6,7,9…”
Method
Metadata
- Authors
- Balaji, V., Balaji, M. S., Alexander, C., Srinivasan, A., Suganthi, S. R., Thiyagarajah, A., & Seshiah, V.
- Venue
- Gynecological Endocrinology
- Publisher
- Informa UK Limited
- Published
- 2012-04-03
- Volume
- 28
- Issue
- 7
- Pages
- 529-532
- ISSN
- 0951-3590 (ISSN-L)
- 1473-0766
- OpenAlex
- W2170431262
- Cited by
- 32
- References
- 3
- FWCI
- 3.50
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Premixed insulin aspart 30 (BIAsp 30) versus premixed human insulin 30 (BHI 30) in gestational diabetes mellitus: a randomized open-label controlled study. https://app.cochat.ai/papers/10.3109/09513590.2011.650661
- The paper
- Balaji, V., Balaji, M. S., Alexander, C., Srinivasan, A., Suganthi, S. R., Thiyagarajah, A., & Seshiah, V. (2012). Premixed insulin aspart 30 (BIAsp 30) versus premixed human insulin 30 (BHI 30) in gestational diabetes mellitus: a randomized open-label controlled study. Gynecological Endocrinology. https://doi.org/10.3109/09513590.2011.650661
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.